Status:
TERMINATED
Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Trubion Pharmaceuticals/Emergent BioSolutions Inc.
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.
Eligibility Criteria
Inclusion
- Clinical diagnosis of active seropositive rheumatoid arthritis on a stable dose of methotrexate (7.5-25 mg weekly) for at least 12 weeks with or without a history of anti-TNF use.
Exclusion
- Any prior use of rituximab or other B cell depleting agents.
- Any significant health problem other than rheumatoid arthritis
- Clinically significant laboratory abnormalities
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
222 Patients enrolled
Trial Details
Trial ID
NCT00634933
Start Date
March 1 2008
End Date
October 1 2012
Last Update
March 11 2013
Active Locations (65)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-7201
2
Pfizer Investigational Site
Paradise Valley, Arizona, United States, 85253
3
Pfizer Investigational Site
Los Angeles, California, United States, 90048
4
Pfizer Investigational Site
Los Angeles, California, United States, 90095